Promising New Treatment for EGFR Mutation-Resistant Non-Small Cell Lung Cancer

Data from a comprehensive analysis show significant promise for sunvozertinib, formerly known as DZD9008, in treating EGFR-tyrosine kinase inhibitor (TKI)-resistant non–small cell lung cancer (NSCLC). This oral medication demonstrates effective antitumor activity while maintaining a favorable safety profile, as evidenced by combined results from three key studies: the international phase 2 WU-KONG1 trial, the phase 1 WU-KONG2 study, and the phase 2 WU-KONG15 trial.

Breaking Down the Studies

The pooled data encompass a total of 40 patients with EGFR-mutated NSCLC who had developed resistance to TKI treatments. The majority of these patients (90%) had received three or more prior lines of therapy, with a median of five lines. Most patients had also undergone prior chemotherapy (90.6%). All participants had previously been treated with at least one EGFR TKI, and 68.8% had received third-generation EGFR TKIs.

Efficacy and Dosage Findings

In all studies, sunvozertinib was administered from 50 mg to 400 mg daily, and antitumor activity was observed even at the lowest dose of 50 mg, irrespective of T790M mutation status. The median age of the patients was 64.5 years, with most being female (68.8%). Approximately 75% of patients had an ECOG performance status of 1, indicating good overall health. Additionally, 34.4% of patients had more than three metastatic sites, and 43.8% had brain metastases.

Eligibility Criteria

Eligibility for the phase 2 WU-KONG15 trial included being 18 years or older, with documented EGFR mutations, and an ECOG performance status of 0 or 1. Patients must have had measurable disease according to RECIST 1.1 criteria and either progressed or been intolerant to standard therapy. Specific cohorts welcomed patients with EGFR exon 20 insertions, EGFR sensitizing mutations, and treatment-naive individuals. Inclusion of those with stable brain metastases was also possible.

The phase 2 WU-KONG1 trial had stricter inclusion requirements, particularly for prior treatment of brain metastases and guidelines for prior therapies. These differences ensured the selection of appropriate patients who could benefit from the treatment.

Developments Moving Forward

Currently, two ongoing global studies are further exploring sunvozertinib’s effectiveness: WU-KONG1 part B, which focuses on second-line settings and beyond, and the phase 3 multinational, randomized WU-KONG28 study, evaluating its role in the first-line setting.

Expert Commentary

“Resistance to chemotherapy or EGFR TKIs remains a critical challenge in managing EGFR-mutated NSCLC,” commented Mengzhao Wang, MD, PhD, from Peking Union Medical College Hospital, China. “Sunvozertinib, an oral, irreversible EGFR TKI, targets a wide array of EGFR mutations while maintaining selectivity for wild-type EGFR. Previous studies highlighted its antitumor activity in various EGFR mutation contexts, and this recent analysis further supports its potential in overcoming resistance to prior EGFR TKI treatments, warranting continued research.”

Regulatory Approvals

In China, sunvozertinib received approval from the National Medical Products Administration (NMPA) in August 2023 for the treatment of advanced NSCLC with EGFR exon20ins after platinum-based chemotherapies, supported by data from the WU-KONG6 study.

Conclusion

The recent pooled analysis of sunvozertinib in treating EGFR mutation-resistant NSCLC presents a promising front in combating this challenging condition. By demonstrating significant antitumor activity and a favorable safety profile, this new oral EGFR TKI offers hope to a wide range of patients who have exhausted other treatment options. Ongoing studies will continue to shed light on sunvozertinib’s potential in the management of non-small cell lung cancer and open new avenues for targeted therapy.

Join the Conversation

What do you think about the potential of sunvozertinib in treating lung cancer? Share your thoughts in the comments below, and subscribe to Archynetys for more updates on the latest medical advancements.